The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.

The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab. Pneumonol Alergol Pol. 2015;83(4):335-8 Authors: Bartuzi Z, Bodzenta-Łukaszyk A, Kuna P, Kupryś-Lipińska I, Niżankowska-Mogilnicka E, Samoliński B PMID: 26166795 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/26166795?dopt=Abstract

Source: Pneumonologia i Alergologia Polska - July 17, 2015 Category: Respiratory Medicine Authors: Bartuzi Z, Bodzenta-Łukaszyk A, Kuna P, Kupryś-Lipińska I, Niżankowska-Mogilnicka E, Samoliński B Tags: Pneumonol Alergol Pol Source Type: research

More News: Allergy & Immunology | Asthma | Respiratory Medicine | Xolair